Shared on 31 Oct 25
Analysts have raised their price targets for Artivion, with increases ranging from $38.80 to $47 per share. They cite the company’s strong core business performance, momentum in its high-growth aortic stent graft segment, and ongoing improvements in margins and profitability.
Shared on 17 Oct 25
Fair value Increased 1.60%Aging Population And Global Approvals Will Advance Cardiac Devices
Artivion's analyst price target has been raised modestly from $44.54 to $45.26, as analysts point to ongoing strength in the company's core business, margin gains, and continued momentum in its Aortic stent graft segment. Analyst Commentary Recent analyst research on Artivion reflects a mix of optimism surrounding the company’s operational progress and a measured approach regarding its future outlook.
Shared on 03 Oct 25
Fair value Increased 5.05%Aging Population And Global Approvals Will Advance Cardiac Devices
Analysts have raised their price target for Artivion by approximately $2.14 to $44.54. This change is based on constructive feedback from cardiac surgeons, positive incremental clinical updates, and ongoing confidence in the company’s growth prospects.
Shared on 08 Aug 25
Fair value Increased 26%Aging Population And Global Approvals Will Advance Cardiac Devices
The significant upward revision in Artivion’s consensus price target reflects improved sentiment, underpinned by rising future P/E and net profit margin, resulting in a new fair value estimate of $38.00. What's in the News Raised 2025 revenue guidance to $435–$443 million, with expected constant currency growth of 12% to 14%.